急性冠動脈症候群診断用の心臓バイオマーカー：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
3 Competitive Assessment 9
3.1 Overview 9
3.2 Cardiac Troponins 10
3.2.1 Overview 10
3.2.2 Clinical Application and Utility 12
3.2.3 Market Penetration 17
3.2.4 SWOT Analysis 17
3.3 Creatine Kinase-MB 18
3.3.1 Overview 18
3.3.2 Clinical Application and Utility 19
3.3.3 Market Penetration 20
3.3.4 SWOT Analysis 20
3.4 Myoglobin 21
3.4.1 Overview 21
3.4.2 Clinical Application and Utility 22
3.4.3 Market Penetration 23
3.4.4 SWOT Analysis 23
3.5 Point-of-Care 24
3.5.1 Overview 24
3.5.2 Clinical Application and Utility 25
3.5.3 Market Penetration 28
3.5.4 SWOT Analysis 29
4 Pipeline Products 30
4.1 Overview 30
4.2 BAG3 (Biouniversia) 31
4.2.1 Overview 31
4.2.2 SWOT Analysis 31
4.3 CAVARISK (Cavadis) 32
4.3.1 Overview 32
4.3.2 SWOT Analysis 32
4.4 CardioScore (BG Medicine) 33
4.4.1 Overview 33
4.4.2 SWOT Analysis 33
4.5 Circulating Endothelial Cells 34
4.5.1 Overview 34
4.5.2 SWOT Analysis 35
4.6 Copeptin (Thermo Scientific) 36
4.6.1 Overview 36
4.6.2 SWOT Analysis 39
4.7 Heart-Type Fatty Acid Binding Protein 40
4.7.1 Overview 40
4.7.2 SWOT Analysis 42
4.8 MIRISK VP Assessment (Aviir) 43
4.8.1 Overview 43
4.8.2 SWOT Analysis 43
4.9 Early Emerging Tests 44
4.9.1 Heart Diagnostic Assay (Prevencio/University of Pittsburgh) 44
4.9.2 Sentinel CVD (GeneNews) 44
4.9.3 SomaScan Cardiovascular Assay (SomaLogic) 44
5 Current and Future Players 45
5.1 Overview 45
5.2 Trends in Corporate Strategy 45
5.3 Abbott Diagnostics 46
5.3.1 Overview 46
5.3.2 Portfolio Assessment 46
5.4 Alere 48
5.4.1 Overview 48
5.4.2 Portfolio Assessment 49
5.5 Beckman Coulter 50
5.5.1 Overview 50
5.5.2 Portfolio Assessment 51
5.6 bioMérieux 52
5.6.1 Overview 52
5.6.2 Portfolio Assessment 53
5.7 Mitsubishi Chemical Medience Corporation 54
5.7.1 Overview 54
5.7.2 Portfolio Assessment 55
5.8 Ortho-Clinical Diagnostics 56
5.8.1 Overview 56
5.8.2 Portfolio Assessment 57
5.9 Radiometer Medical 58
5.9.1 Overview 58
5.9.2 Portfolio Assessment 59
5.10 Randox Laboratories 60
5.10.1 Overview 60
5.10.2 Portfolio Assessment 61
5.11 Response Biomedical 62
5.11.1 Overview 62
5.11.2 Portfolio Assessment 63
5.12 Roche Diagnostics 64
5.12.1 Overview 64
5.12.2 Portfolio Assessment 64
5.13 Siemens Healthcare 66
5.13.1 Overview 66
5.13.2 Portfolio Assessment 67
5.14 Thermo Scientific 68
5.14.1 Overview 68
5.14.2 Portfolio Assessment 69
6 Appendix 70
6.1 Bibliography 70
6.2 Abbreviations 81
6.3 Research Methodology 83
6.3.1 Overview 83
6.3.2 Coverage 83
6.3.3 Secondary Research 83
6.3.4 Forecast Methodology 84
6.4 Primary Research 85
6.5 Physicians and Specialists Included in this Study 86
6.6 About the Authors 87
6.6.1 Analysts 87
6.6.2 Global Head of Healthcare 88
6.7 About MediPoint 89
6.8 About GlobalData 89
6.9 Contact Us 89
6.10 Disclaimer 89